ClinicalTrials.gg
Active, not recruitingNCT03775486ORIONUpdated Sep 11, 2026Results posted

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

A Phase 2 interventional study of Durvalumab and Placebo for Olaparib in Non-small Cell Lung Cancer NSCLC, sponsored by AstraZeneca. Active, not recruiting at 68 sites in 12 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 5 under way, 1 of them phase 3. olaparib · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 11
401 · median 186
Started
2018
the only one that year
Phase 2
7 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
2 of 11
AstraZeneca

Among the 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 2, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following Standard of Care (SoC) platinum-based chemotherapy with Durvalumab as first-line treatment in patients with Stage IV non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

Read the detailed description

Adult patients with a histologically or cytologically documented advanced NSCLC not amenable to curative surgery or radiation with tumors that lack activation EGFR mutations and ALK fusions are eligible for enrollment. During the initial therapy phase, patients will receive treatment with Durvalumab along with the Investigator's choice of platinum-based doublet therapy for squamous NSCLC (nab-paclitaxel plus carboplatin or gemcitabine plus carboplatin/cisplatin) and non-squamous NSCLC (nab-paclitaxel plus carboplatin or pemetrexed plus carboplatin/cisplatin) for 4 cycles. Patients who have completed 4 cycles and not progressed throughout the initial therapy phase will be randomized in a 1:1 ratio into the maintenance phase of the study to receive either Durvalumab plus placebo or Durvalumab plus Olaparib maintenance therapy. Patients will receive maintenance treatment until specific discontinuation criteria are met, including clinical disease progression (as assessed by the Investigator) or RECIST 1.1-defined radiological Progressive Disease (PD), unacceptable toxicity, and withdrawal of consent. Tumor evaluation scans will be performed until objective disease progression as efficacy assessments. All patients will be followed for survival until the end of the study.

03

Conditions studied

  • Non-small Cell Lung Cancer NSCLC

Keywords

  • NSCLC
  • Durvalumab
  • Olaparib
  • Maintenance
  • Homologous Recombination Repair (HRR)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation.

Patients must have tumors that lack activating EGFR mutations and ALK fusions.

  • (WHO)/() performance status of 0 or 1
  • No prior chemotherapy or any other systemic therapy for Stage IV NSCLC
  • Adequate organ and marrow function without blood transfusions in the past 28 days,
  • At least 1 tumor lesion, not previously irradiated, that can be accurately measured as per 1.1.

Key Inclusion criteria for randomization to maintenance treatment:

  • Documented radiographic evidence of CR, PR, or Stable Disease (SD) as per Investigator-assessed RECIST 1.1 following 4 cycles of platinum-based chemotherapy.
  • (CrCl) ≥51 mL/min calculated by the investigator or designee using the Cockcroft-Gault equation or measured by 24-hour urine collection.
  • Ability to swallow whole oral medications.
  • All patients must provide a formalin-fixed, paraffin embedded tumor sample for tissue-based immunohistochemistry staining and DNA sequencing to determine expression, HRRm status, and other correlatives: either newly acquired or (\<3 years old) are acceptable. If available, a newly acquired tumor biopsy, collected as part of routine clinical practice, is preferred. If not available, an archival sample taken \<3 years prior to screening is acceptable. If both an archival sample and a fresh tumor biopsy sample are available, both samples should be submitted for analysis and must be submitted as different samples using different accession numbers. Slides from different blocks cannot be mixed and submitted with the same kit.

Exclusion criteria

Exclusion criteria

  • Mixed small-cell lung cancer and sarcomatoid variant NSCLC histology.
  • Prior exposure to any chemotherapy agents (except chemotherapy or chemoradiation for non- disease), polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerase (PARP) therapy, or immunomediated therapy
  • Active or prior documented or inflammatory disorders.
  • Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
  • Current or prior use of medication within 14 days before the first dose of Product (IP)
  • untreated (CNS) metastases and/or carcinomatous meningitis
  • Active infection.

Exclusion criteria to be randomized to maintenance treatment:

  • Inability to complete 4 cycles of platinum-based chemotherapy for any reason or discontinuation of Durvalumab during initial therapy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Durvalumab/Olaparib Combination Therapy

    Durvalumab/Olaparib Combination Therapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)

    Drug: Durvalumab · Drug: Olaparib · Drug: Nab-paclitaxel+carboplatin · Drug: Gemcitabine+carboplatin · Drug: Pemetrexed+carboplatin · Drug: Gemcitabine+cisplatin · Drug: Pemetrexed+cisplatin

  • Experimental
    Durvalumab Monotherapy

    Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)

    Drug: Durvalumab · Drug: Placebo for Olaparib · Drug: Nab-paclitaxel+carboplatin · Drug: Gemcitabine+carboplatin · Drug: Pemetrexed+carboplatin · Drug: Gemcitabine+cisplatin · Drug: Pemetrexed+cisplatin

Interventions

  • Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.

    Also known as: MEDI4736 (Durvalumab)

  • DrugPlacebo for Olaparib

    Matching tablet

    Also known as: Placebo

  • 150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required

    Also known as: AZD2281 (Olaparib)

  • DrugNab-paclitaxel+carboplatin

    Drug pages: Albumin-Bound Paclitaxel · Carboplatin

    Standard of Care chemotherapy (squamous and non-squamous patients)

  • DrugGemcitabine+carboplatin

    Drug pages: Gemcitabine · Carboplatin

    Standard of Care chemotherapy (squamous patients only)

  • DrugPemetrexed+carboplatin

    Drug pages: Pemetrexed · Carboplatin

    Standard of Care chemotherapy (non-squamous patients only)

  • DrugGemcitabine+cisplatin

    Drug pages: Gemcitabine · Cisplatin

    Standard of Care chemotherapy (squamous patients only)

  • DrugPemetrexed+cisplatin

    Drug pages: Pemetrexed · Cisplatin

    Standard of Care chemotherapy (non-squamous patients only)

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival (PFS) based on investigator assessments according to Response Evaluation Criteria in Solid Tumours version 1.1. PFS is defined as time from date of randomization until the date of objective radiological disease progression using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).

    Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) across the maintenance phase. OS is defined as time from date of randomization until the date of death by any cause

    Time frame: From randomization until the date of death due to any cause, up to 18 months.

  2. Objective Response Rate

    Objective response rate (ORR) defined as number of participants with complete response (CR) or partial response (PR) after randomization

    Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months

  3. Duration of Response

    Duration of response (DoR) defined as time from the date of first documented response following randomization until the first date of documented progression or death in the absence of disease progression. Percentage of participants remaining in response at 3, 6, 9 and 12 months estimated using the Kaplan-Meier method.

    Time frame: From date of first documented response until objective radiological disease progression or death, up to 18 months.

  4. Progression-free Survival in Homologous Recombination Repair Related Gene Mutation (HRRm) Population

    Progression-free survival in homologous recombination repair related gene mutation (HRRm) population defined as time from date of randomization until the date of objective radiological disease progression in HRRm population using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).

    Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months

  5. Concentration of Durvalumab

    Concentration (pharmacokinetics) of durvalumab

    Time frame: Assessed from start of initial therapy up to 2 years.

  6. Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13

    Disease-related symptoms assessed by change from baseline (for maintenance phase) in EORTC QLQ-LC13. Average adjusted mean over first 11 cycles is presented. The EORTC QLQ-LC13 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales in the EORTC QLQ-LC13. Higher scores on symptom scales represent greater symptom severity.

    Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months

  7. Time to Deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13

    Disease-related symptoms assessed by time to deterioration (for maintenance phase) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13. Symptom deterioration is defined as an increase in the score from baseline of less than or equal to 10) that is confirmed at a subsequent assessment, or death (by any cause) in the absence of a clinically meaningful symptom deterioration. NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.

    Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months

  8. Change From Baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30

    Disease-related symptoms and health-related quality of life (HRQoL) assessed by change from baseline (for maintenance phase) in EORTC QLQ-C30. Average adjusted mean over first 11 cycles is presented. The EORTC QLQ-C30 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales, each of the function scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and function scales indicate better health status/function. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / quality of life (QoL) represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: Includes all assessments occurring within the first 12 months of randomization or until disease progression, up to 18 months.

  9. Time to Deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30

    Disease-related symptoms and health-related quality of life (HRQoL) assessed by time to deterioration (for maintenance phase) in EORTC QLQ-C30. NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.

    Time frame: From randomization until date of first symptom deterioration that is confirmed, up to 18 months.

  10. Presence of Anti-drug Antibodies (ADAs) for Durvalumab

    Presence of anti-drug antibodies (ADAs) for durvalumab, as assessed at 3, 6, 12, 16 and 20 weeks after start of treatment and every 12 weeks thereafter until 3 and 6 months after last dose of durvalumab

    Time frame: Assessed from start of initial therapy up to 2 years.

  11. Number of Participants With Treatment-Related Adverse Events

    Number of Participants with Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)

    Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months

07

Results

Posted Dec 12, 2022

Participant flow

Initial Therapy Phase
Participant flow — Initial Therapy Phase
MilestoneDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
Started0401
Completed0269
Not completed0132
Withdrew: Other reason provided015
Withdrew: Condition under investigation worsened067
Withdrew: Protocol violation02
Withdrew: Adverse event034
Withdrew: Withdrawal by subject014
Maintenance Phase
Participant flow — Maintenance Phase
MilestoneDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
Started134135
Participants who received durvalumab134134
Participants who received olaparib/placebo128128
Participants who terminated the study5757
Completed7778
Not completed5757
Withdrew: Withdrawal by subject1312
Withdrew: Death4445

Outcome measures

PrimaryProgression-free Survival

Progression-free survival (PFS) based on investigator assessments according to Response Evaluation Criteria in Solid Tumours version 1.1. PFS is defined as time from date of randomization until the date of objective radiological disease progression using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).

Time frame:
From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Reported as:
Count of participants · Participants
Progression-free Survival
ParticipantsDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
RECIST progression: Target Lesions4063
RECIST progression: Non Target Lesions2830
RECIST progression: New Lesions4439
Death in the absence of progression89
Censored subjects: Censored RECIST progression00
Censored subjects: Censored death10
Censored subjects: Progression-free at time of analysis4434
Censored subjects: Progression-free prior to lost to follow-up00
Censored subjects: Progression-free prior to withdrawal of consent32
Censored subjects: Progression-free prior to discontinuation due to other reason00
Censored subjects: No post-baseline evaluable tumor assessment22
Statistical analysis
  • Durvalumab/Olaparib Combination Therapy vs Durvalumab/Placebo Therapy · Log Rank · p = 0.074 · Hazard ratio (hr): 0.76 · 95% CI 0.57 to 1.02
  • Durvalumab/Olaparib Combination Therapy · Median: 7.2 · 95% CI 5.3 to 7.9
  • Durvalumab/Placebo Therapy · Median: 5.3 · 95% CI 3.7 to 5.8
SecondaryOverall Survival

Overall survival (OS) across the maintenance phase. OS is defined as time from date of randomization until the date of death by any cause

Time frame:
From randomization until the date of death due to any cause, up to 18 months.
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
Death4445
Censored participants (still in survival at follow up or terminated study prior to death)9090
Statistical analysis
  • Durvalumab/Olaparib Combination Therapy vs Durvalumab/Placebo Therapy · Log Rank · p = 0.604 · Hazard ratio (hr): 0.90 · 95% CI 0.59 to 1.36
  • Durvalumab/Olaparib Combination Therapy · Median: 17.4
  • Durvalumab/Placebo Therapy · Median overall survival (months): 11.8The CI lower limit is included as the estimated value as there was an insufficient number of participants with events to calculate a median value
SecondaryObjective Response Rate

Objective response rate (ORR) defined as number of participants with complete response (CR) or partial response (PR) after randomization

Time frame:
From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
Response2218
No Response107113
SecondaryDuration of Response

Duration of response (DoR) defined as time from the date of first documented response following randomization until the first date of documented progression or death in the absence of disease progression. Percentage of participants remaining in response at 3, 6, 9 and 12 months estimated using the Kaplan-Meier method.

Time frame:
From date of first documented response until objective radiological disease progression or death, up to 18 months.
Reported as:
Number · percent
Duration of Response
percentDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
Percentage of participants remaining in response at 3 months90.585.1
Percentage of participants remaining in response at 6 months79.165.7
Percentage of participants remaining in response at 9 months69.265.7
Percentage of participants remaining in response at 12 months69.265.7
Statistical analysis
  • Durvalumab/Olaparib Combination Therapy · Median duration of response: 6.5The CI lower limit is included as the estimated value as there was an insufficient number of participants with events to calculate a median value
  • Durvalumab/Placebo Therapy · Median duration of response: 3.8The CI lower limit is included as the estimated value as there was an insufficient number of participants with events to calculate a median value
SecondaryProgression-free Survival in Homologous Recombination Repair Related Gene Mutation (HRRm) Population

Progression-free survival in homologous recombination repair related gene mutation (HRRm) population defined as time from date of randomization until the date of objective radiological disease progression in HRRm population using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).

Time frame:
From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Reported as:
Count of participants · Participants
Progression-free Survival in Homologous Recombination Repair Related Gene Mutation (HRRm) Population
ParticipantsDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
RECIST progression: Target Lesions15
RECIST progression: Non Target Lesions22
RECIST progression: New Lesions33
Death in the absence of progression00
Censored subjects: Censored RECIST progression00
Censored subjects: Censored death00
Censored subjects: Progression-free at time of analysis22
Censored subjects: Progression-free prior to lost to follow-up00
Censored subjects: Progression-free prior to withdrawal of consent00
Censored subjects: Progression-free prior to discontinuation due to other reason00
Censored subjects: No post-baseline evaluable tumor assessment00
Statistical analysis
  • Durvalumab/Olaparib Combination Therapy vs Durvalumab/Placebo Therapy · Hazard ratio (hr): 0.46 · 95% CI 0.07 to 2.00
  • Durvalumab/Olaparib Combination Therapy · Median (months): 3.7
  • Durvalumab/Placebo Therapy · Median (months): 3.7 · 95% CI 1.2 to 16.6
SecondaryConcentration of Durvalumab

Concentration (pharmacokinetics) of durvalumab

Time frame:
Assessed from start of initial therapy up to 2 years.
Reported as:
Geometric mean · μg/mL
Concentration of Durvalumab
μg/mLDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
Cycle 01 Day 01 (Initial Therapy Phase) Post dose417.152 ± 62.694453.724 ± 43.258
Cycle 02 Day 01 (Initial Therapy Phase) Pre dose76.812 ± 84.58676.959 ± 71.104
Cycle 04 Day 01 (Initial Therapy Phase) Pre dose155.461 ± 58.251154.947 ± 50.102
Cycle 01 (Maintenance Phase) Post dose535.078 ± 40.119524.306 ± 56.458
Cycle 02 (Maintenance Phase) Pre dose159.157 ± 53.813160.315 ± 54.409
Cycle 05 (Maintenance Phase) Pre dose166.644 ± 54.948147.848 ± 56.204
Cycle 08 (Maintenance Phase) Pre dose198.932 ± 47.024154.057 ± 54.911
Cycle 11 (Maintenance Phase) Pre dose210.794 ± 42.117186.092 ± 39.823
Cycle 14 (Maintenance Phase) Pre dose276.612 ± 50.137182.042 ± 39.341
Cycle 17 (Maintenance Phase) Pre dose264.096 ± 55.519217.137 ± 92.229
Cycle 20 (Maintenance Phase) Pre dose528.046112.276
Month 03 (Maintenance Phase) Pre dose12.289 ± 450.12512.769 ± 225.898
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13

Disease-related symptoms assessed by change from baseline (for maintenance phase) in EORTC QLQ-LC13. Average adjusted mean over first 11 cycles is presented. The EORTC QLQ-LC13 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales in the EORTC QLQ-LC13. Higher scores on symptom scales represent greater symptom severity.

Time frame:
From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Reported as:
Mean · change from baseline score
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13
change from baseline scoreDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
EORTC QLQ-LC13: Dyspnoea-1.27 ± 1.373-0.76 ± 1.500
EORTC QLQ-LC13: Coughing-2.14 ± 1.980-3.09 ± 2.172
EORTC QLQ-LC13: Pain in chest1.31 ± 1.4103.57 ± 1.575
Statistical analysis
  • Durvalumab/Olaparib Combination Therapy vs Durvalumab/Placebo Therapy · Estimated difference in adjusted mean: -0.51 · 95% CI -4.47 to 3.46
  • Durvalumab/Olaparib Combination Therapy vs Durvalumab/Placebo Therapy · Estimated difference in adjusted mean: 0.95 · 95% CI -4.81 to 6.71
  • Durvalumab/Olaparib Combination Therapy vs Durvalumab/Placebo Therapy · Estimated difference in adjusted mean: -2.26 · 95% CI -6.39 to 1.88
SecondaryTime to Deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13

Disease-related symptoms assessed by time to deterioration (for maintenance phase) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13. Symptom deterioration is defined as an increase in the score from baseline of less than or equal to 10) that is confirmed at a subsequent assessment, or death (by any cause) in the absence of a clinically meaningful symptom deterioration. NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.

Time frame:
From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Reported as:
Median · months
Time to Deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13
monthsDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
EORTC QLQ-LC13: Dyspnoea10.0 (5.6 to 12.2)9.7 (6.9 to 12.0)
EORTC QLQ-LC13: Coughing11.7 (9.3 to NA)10.6 (7.7 to 12.6)
EORTC QLQ-LC13: Haemoptysis15.0 (11.7 to NA)12.6 (10.9 to NA)
EORTC QLQ-LC13: Pain In Chest13.8 (10.8 to NA)11.5 (9.5 to NA)
EORTC QLQ-LC13: Pain In Arm Or Shoulder15.0 (10.2 to NA)9.7 (7.4 to 12.6)
EORTC QLQ-LC13: Pain In Other Parts10.3 (8.8 to 12.2)10.6 (8.6 to NA)
SecondaryChange From Baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30

Disease-related symptoms and health-related quality of life (HRQoL) assessed by change from baseline (for maintenance phase) in EORTC QLQ-C30. Average adjusted mean over first 11 cycles is presented. The EORTC QLQ-C30 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales, each of the function scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and function scales indicate better health status/function. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / quality of life (QoL) represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

Time frame:
Includes all assessments occurring within the first 12 months of randomization or until disease progression, up to 18 months.
Reported as:
Mean · change from baseline score
Change From Baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30
change from baseline scoreDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
EORTC QLQ-C30: Fatigue0.15 ± 1.327-1.49 ± 1.456
EORTC QLQ-C30: Appetite loss-0.13 ± 1.613-3.35 ± 1.779
Statistical analysis
  • Durvalumab/Olaparib Combination Therapy vs Durvalumab/Placebo Therapy · Estimated difference in adjusted mean: 1.64 · 95% CI -2.20 to 5.47
  • Durvalumab/Olaparib Combination Therapy vs Durvalumab/Placebo Therapy · Estimated difference in adjusted mean: 3.22 · 95% CI -1.46 to 7.90
SecondaryTime to Deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30

Disease-related symptoms and health-related quality of life (HRQoL) assessed by time to deterioration (for maintenance phase) in EORTC QLQ-C30. NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.

Time frame:
From randomization until date of first symptom deterioration that is confirmed, up to 18 months.
Reported as:
Median · time to deterioration (months)
Time to Deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30
time to deterioration (months)Durvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
EORTC QLQ-C30: Fatigue8.8 (5.6 to 10.8)10 (8.0 to 12.6)
EORTC QLQ-C30: Nausea And Vomiting12.2 (10.2 to 15.0)12.6 (9.7 to NA)
EORTC QLQ-C30: Pain10.2 (7.4 to 12.2)9.7 (6.6 to 12.6)
EORTC QLQ-C30: Dyspnoea12.2 (10.0 to NA)11.0 (8.8 to NA)
EORTC QLQ-C30: Insomnia13.8 (10.0 to NA)10.6 (8.6 to 12.6)
EORTC QLQ-C30: Appetite Loss11.7 (10.1 to NA)11.5 (10.0 to NA)
EORTC QLQ-C30: Constipation12.2 (10.0 to NA)12.0 (10.0 to NA)
EORTC QLQ-C30: Diarrhoea13.8 (10.2 to NA)11.5 (9.7 to NA)
Physical Functioning12.0 (9.3 to NA)12.0 (9.0 to NA)
Role Functioning10.0 (5.6 to 12.2)10.6 (8.8 to NA)
Emotional Functioning12.2 (9.3 to NA)11.0 (8.8 to 12.6)
Cognitive Functioning10.2 (6.9 to NA)10.6 (8.6 to 12.6)
Social Functioning9.3 (7.4 to 12.2)10.0 (7.7 to NA)
Global Health Status/Quality of Life10.2 (6.5 to 12.2)9.7 (7.4 to 12.0)
SecondaryPresence of Anti-drug Antibodies (ADAs) for Durvalumab

Presence of anti-drug antibodies (ADAs) for durvalumab, as assessed at 3, 6, 12, 16 and 20 weeks after start of treatment and every 12 weeks thereafter until 3 and 6 months after last dose of durvalumab

Time frame:
Assessed from start of initial therapy up to 2 years.
Reported as:
Count of participants · Participants
Presence of Anti-drug Antibodies (ADAs) for Durvalumab
ParticipantsDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
ADA prevalence (any ADA positive, baseline or post-baseline)119
ADA incidence (treatment-induced or treatment-boosted)54
ADA positive post-baseline and positive at baseline01
ADA positive post-baseline and not detected at baseline (treatment-induced)54
ADA not detected at post-baseline and positive at baseline64
Treatment-boosted ADA00
Persistent positive03
Transient positive52
Neutralizing anti-drug antibody positive at any visit11
SecondaryNumber of Participants With Treatment-Related Adverse Events

Number of Participants with Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)

Time frame:
From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Adverse Events
ParticipantsDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
Number of Participants With Treatment-Related Adverse Events8354

Adverse events

Collected over From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Therapy Phase89/401 (22.2%)104/401 (25.9%)368/401 (91.8%)
Durvalumab/Olaparib Combination Therapy44/134 (32.8%)25/134 (18.7%)116/134 (86.6%)
Durvalumab/Placebo Therapy45/135 (33.3%)19/134 (14.2%)104/134 (77.6%)
Most frequent serious events
Showing 10 of 121
Most frequent serious events
EventInitial Therapy PhaseDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
PneumoniaInfections and infestations16/4013/1342/134
AnaemiaBlood and lymphatic system disorders13/4015/1340/134
NeutropeniaBlood and lymphatic system disorders6/4011/1340/134
ThrombocytopeniaBlood and lymphatic system disorders6/4010/1340/134
Atrial fibrillationCardiac disorders0/4012/1340/134
DyspnoeaRespiratory, thoracic and mediastinal disorders2/4011/1342/134
HaemoptysisRespiratory, thoracic and mediastinal disorders2/4010/1342/134
Disease progressionGeneral disorders1/4010/1342/134
Febrile neutropeniaBlood and lymphatic system disorders4/4010/1341/134
DehydrationMetabolism and nutrition disorders4/4010/1340/134
Most frequent other events
Showing 10 of 24
Most frequent other events
EventInitial Therapy PhaseDurvalumab/Olaparib Combination TherapyDurvalumab/Placebo Therapy
AnaemiaBlood and lymphatic system disorders188/40135/13411/134
NauseaGastrointestinal disorders118/40119/13410/134
NeutropeniaBlood and lymphatic system disorders92/4010/1340/134
ConstipationGastrointestinal disorders70/4010/1340/134
FatigueGeneral disorders68/40115/1349/134
ThrombocytopeniaBlood and lymphatic system disorders60/4010/1340/134
DiarrhoeaGastrointestinal disorders53/40111/1346/134
LeukopeniaBlood and lymphatic system disorders49/4010/1340/134
Decreased appetiteMetabolism and nutrition disorders1/40116/1349/134
Neutrophil count decreasedInvestigations46/4010/1340/134

Baseline characteristics

The full analysis set for the maintenance phase is presented

Age, Continuous
Age, Continuous(Years)Durvalumab/Olaparib Combination TherapyDurvalumab/Placebo TherapyTotal
Mean age (years)65.9 ± 9.5963.0 ± 9.5064.5 ± 9.64
Age, Customized
Age, Customized(participants)Durvalumab/Olaparib Combination TherapyDurvalumab/Placebo TherapyTotal
Less than 50 years71421
Equal to or greater than 50 years to less than 65 years4955104
Equal to or greater than 65 years to less than 75 years5454108
Equal to or greater than 75 years241236
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab/Olaparib Combination TherapyDurvalumab/Placebo TherapyTotal
Female363874
Male9897195
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Durvalumab/Olaparib Combination TherapyDurvalumab/Placebo TherapyTotal
Hispanic or Latino235
Not Hispanic or Latino132132264
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Durvalumab/Olaparib Combination TherapyDurvalumab/Placebo TherapyTotal
American Indian or Alaska Native000
Asian374582
Native Hawaiian or Other Pacific Islander000
Black or African American112
White9689185
More than one race000
Unknown or Not Reported000
Smoking Status
Smoking Status(Participants)Durvalumab/Olaparib Combination TherapyDurvalumab/Placebo TherapyTotal
Current353166
Former7472146
Never253257
Histology Type
Histology Type(participants)Durvalumab/Olaparib Combination TherapyDurvalumab/Placebo TherapyTotal
Squamous Cell Carcinoma5859117
Nonsquamous Cell Carcinoma7676152
World Health Organization/Eastern Cooperative Oncology Group
World Health Organization/Eastern Cooperative Oncology Group(participants)Durvalumab/Olaparib Combination TherapyDurvalumab/Placebo TherapyTotal
Normal Activity5254106
Restricted Activity8180161
In Bed Less Than or Equal to 50 percent of the Time112
08

Study locations

68 sites
  • Research Site
    Bonita Springs, Florida 34135, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Tallahassee, Florida 32308-5304, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Kansas City, Missouri 64132, United States
  • Research Site
    Bethlehem, Pennsylvania 18015, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Aalst, 9300, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Budapest, 1088, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Deszk, 6772, Hungary
  • Research Site
    Farkasgyepü, 8582, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Ahmedabad, 380009, India
  • Research Site
    Ahmedabad, 380053, India
  • Research Site
    Jamnagar, 361008, India
  • Research Site
    Kochi, 682026, India
  • Research Site
    Mysuru, 570021, India
  • Research Site
    Nashik, 422004, India
  • Research Site
    Nashik, 422009, India
  • Research Site
    Pune, 411001, India
  • Research Site
    Thiruvananthapuram, 695011, India
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Kurume-shi,, 830-0011, Japan
  • Research Site
    Matsuyama, 791-0280, Japan
  • Research Site
    Nagoya, 460-0001, Japan
  • Research Site
    Sendai, 980-0873, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Ube-shi, 755-0241, Japan
  • Research Site
    Chihuahua City, 31200, Mexico
  • Research Site
    Culiacán, 80230, Mexico
  • Research Site
    San Luis Potosí City, 78250, Mexico
  • Research Site
    Blaricum, 1261, Netherlands
  • Research Site
    Harderwijk, 3844, Netherlands
  • Research Site
    Tilburg, 5022 GC, Netherlands
  • Research Site
    Bialystok, 15-540, Poland
  • Research Site
    Lodz, 90-302, Poland
  • Research Site
    Poznan, 60-693, Poland
  • Research Site
    Prabuty, 82-550, Poland
  • Research Site
    Arkhangelsk, 163045, Russia
  • Research Site
    Chelyabinsk, 454092, Russia
  • Research Site
    Kursk, 305524, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Nal'chik, 360000, Russia
  • Research Site
    P. Herzen Moscow Oncology Rese, 125284, Russia
  • Research Site
    Saint Petersburg, 197022, Russia
  • Research Site
    Sochi, 354000, Russia
  • Research Site
    Yaroslavl, 150054, Russia
  • Research Site
    Dongjakgu, 07061, South Korea
  • Research Site
    Goyang-si, 10408, South Korea
  • Research Site
    Seodaemun-gu, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Suweonsi Paldalgu, 16247, South Korea
  • Research Site
    Dnipro, 49102, Ukraine
  • Research Site
    Kharkiv Region, 61024, Ukraine
  • Research Site
    Kirovohrad, 25006, Ukraine
  • Research Site
    Odesa, 65055, Ukraine
  • Research Site
    Uzhhorod, 88000, Ukraine
  • Research Site
    Zaporizhzhya, 69059, Ukraine
  • Research Site
    Dundee, DD1 9SY, United Kingdom
  • Research Site
    Hull, HU6 7RX, United Kingdom
09

References and documents

Publications

  • Ahn MJ, Bondarenko I, Kalinka E, Cho BC, Sugawara S, Galffy G, Shim BY, Kislov N, Nagarkar R, Demedts I, Gans SJM, Mendoza Oliva D, Stewart R, Lai Z, Mann H, Shi X, Hussein M. Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study. J Thorac Oncol. 2023 Nov;18(11):1594-1606. doi: 10.1016/j.jtho.2023.06.013. Epub 2023 Jun 29. PubMed 37390980 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jan 2021, 24 months.

Results were first posted in Dec 2022, 1 year 11 months after primary completion. A results delay was requested in Dec 2021.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 24 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2018
First posted
Dec 14, 2018
StartActual
Dec 21, 2018
Primary completionActual
Jan 11, 2021
CompletionEst.
Sep 27, 2026
Results delay requested
Dec 8, 2021
Results first posted
Dec 12, 2022
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03775486
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 14, 2018
Start date
Dec 21, 2018
Primary completion
Jan 11, 2021
Completion
Sep 27, 2026 (estimated)
Results posted
Dec 12, 2022
Last update
Sep 11, 2026

Study contacts

Myung-Ju Ahn, MD
principal investigator · Sungkyunkwan University School of Medicine, 135-710, Seoul, Korea

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion